JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
171
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (149 trials with phase data)• Click on a phase to view related trials
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Conditions
- HER2-positive Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 125
- Registration Number
- NCT07102381
- Locations
- 🇺🇸
Texas Oncology DFW, Dallas, Texas, United States
🇺🇸Texas Oncology Gulf Coast, Houston, Texas, United States
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT06961266
- Locations
- 🇺🇸
Clinical Trial Site, Columbia, South Carolina, United States
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Conditions
- Breast CancerGastric CancerEsophageal CancerGastroesophageal CancerColorectal CancerEndometrial CancerNon-small Cell Lung CancerOvarian CancerUrothelial CarcinomaSalivary Gland Cancer
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06695845
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Littleton, Colorado, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Metastatic HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- 🇺🇸
Mayo Clinic Scottsdale - PPDS, Phoenix, Arizona, United States
🇺🇸Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
🇺🇸AdventHealth Hematology and Oncology, Orlando, Florida, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 32
- Next
News
Amneal Receives FDA Approval for Generic Sodium Oxybate, Breaking Jazz Pharmaceuticals' Monopoly in Narcolepsy Treatment
Amneal Pharmaceuticals received FDA approval for its generic sodium oxybate oral solution 500 mg/mL, referencing Jazz Pharmaceuticals' Xyrem for narcolepsy treatment.
Avadel Pharmaceuticals Acquires Exclusive Global Rights to Valiloxybate for Sleep Disorders
Avadel Pharmaceuticals has secured exclusive global licensing rights to valiloxybate from XWPharma for $20 million upfront, with potential milestone payments exceeding $205 million.
Jazz Pharmaceuticals Acquires Exclusive Rights to Epilepsy Drug SAN2355 in $42.5M Deal
Jazz Pharmaceuticals has entered into an exclusive global licensing agreement with Saniona for SAN2355, a preclinical epilepsy drug candidate, paying $42.5 million upfront.
Major Pharma M&A Surge and Landmark Antitrust Rulings Shape 2025 Life Sciences Landscape
The first half of 2025 witnessed unprecedented M&A activity with major deals including Merck's $3.9 billion SpringWorks acquisition, Sanofi's $9.5 billion Blueprint Medicines purchase, and Johnson & Johnson's $14.6 billion Intra-Cellular Therapies acquisition.
Cardiol Therapeutics Stock Plunges 20% as CBD-Based CardiolRx Misses Primary Endpoints in Myocarditis Trial
Cardiol Therapeutics' cannabidiol-based therapy CardiolRx failed to meet co-primary endpoints in the Phase II ARCHER trial for myocarditis, with extracellular volume reduction missing statistical significance (p=0.0538).
FDA Grants First Accelerated Approval for H3 K27M-Mutated Diffuse Midline Glioma with Dordaviprone
The FDA has granted accelerated approval to dordaviprone (Modeyso) for adult and pediatric patients aged 1 year and older with H3 K27M-mutated diffuse midline glioma following disease progression after prior therapy.
Jazz Pharmaceuticals Names Renee Gala as CEO in Strategic Leadership Transition
Jazz Pharmaceuticals' Board of Directors unanimously selected Renee Gala as President and CEO, effective August 11, 2025, succeeding co-founder Bruce Cozadd who will remain as Board Chairperson.
MMJ International Advances First Plant-Based Cannabis Drug MMJ-001 for Huntington's Disease Chorea
MMJ International has developed MMJ-001, a pharmaceutical-grade cannabis drug containing natural THC and CBD extracts specifically formulated for chorea associated with Huntington's Disease.
Xenon Pharmaceuticals Appoints Darren Cline as Chief Commercial Officer Ahead of Azetukalner Phase 3 Data
Xenon Pharmaceuticals has appointed Darren Cline as Chief Commercial Officer to lead commercial strategy for azetukalner, the company's lead Phase 3 candidate targeting epilepsy, major depressive disorder, and bipolar depression.
China Approves Zanidatamab as First Dual HER2-Targeted Bispecific Antibody for Biliary Tract Cancer
China's National Medical Products Administration granted conditional approval to zanidatamab for previously treated, unresectable or metastatic HER2-positive biliary tract cancer, marking the first dual HER2-targeted bispecific antibody approved for this indication in China.